| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 601.524 | 556.950 | 603.594 | 658.776 | 691.895 | 798.464 | 824.008 | 896.391 | 958.216 | 1.060.914 |
| Total Income - EUR | 602.659 | 562.194 | 603.882 | 660.027 | 692.519 | 807.274 | 835.010 | 897.438 | 959.220 | 1.062.159 |
| Total Expenses - EUR | 544.970 | 508.058 | 549.883 | 603.129 | 631.343 | 720.771 | 739.301 | 781.613 | 863.165 | 966.609 |
| Gross Profit/Loss - EUR | 57.690 | 54.136 | 53.999 | 56.899 | 61.176 | 86.503 | 95.708 | 115.825 | 96.055 | 95.550 |
| Net Profit/Loss - EUR | 47.939 | 45.039 | 44.204 | 50.169 | 54.094 | 78.912 | 88.750 | 107.070 | 82.362 | 78.694 |
| Employees | 6 | 7 | 7 | 7 | 7 | 6 | 7 | 7 | 7 | 6 |
Check the financial reports for the company - Verofarm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 52.901 | 76.913 | 63.007 | 79.745 | 79.931 | 62.758 | 49.537 | 38.508 | 67.091 | 82.835 |
| Current Assets | 217.057 | 134.233 | 178.391 | 233.309 | 245.640 | 226.452 | 312.519 | 291.176 | 415.280 | 296.153 |
| Inventories | 97.514 | 78.289 | 64.888 | 58.259 | 85.435 | 110.786 | 133.201 | 135.045 | 151.540 | 139.778 |
| Receivables | 112.785 | 32.462 | 111.853 | 173.492 | 156.700 | 111.739 | 176.669 | 150.682 | 241.515 | 134.424 |
| Cash | 6.758 | 23.482 | 1.650 | 1.558 | 3.505 | 3.928 | 2.649 | 5.449 | 22.225 | 21.950 |
| Shareholders Funds | 191.222 | 117.093 | 146.182 | 203.023 | 182.377 | 137.191 | 199.856 | 165.453 | 278.338 | 167.426 |
| Social Capital | 819 | 811 | 797 | 782 | 767 | 753 | 736 | 738 | 736 | 732 |
| Debts | 79.270 | 95.057 | 95.683 | 110.193 | 143.434 | 152.657 | 162.382 | 164.413 | 204.033 | 212.980 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Verofarm Srl